Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Paul Guillod

Pain Medicine Evanston, IL Medical Doctor

NPI 1215464383 CMS profile 11300349

2650 Ridge Ave., Evanston, IL 60201

Open in the dashboard

General payments

$19,385

198 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Guillod of Evanston, IL is reported in the CMS Open Payments database as having received $19,385 across 198 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,424 68
2024 General $2,625 29
2023 General $2,149 33
2022 General $6,777 51
2021 General $2,410 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Guillod
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Paul Guillod were reported at $5,424. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Paul Guillod Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $2,410 $399 $112–$1,219 $132
2022 $6,777 $455 $137–$1,484 $149
2023 $2,149 $484 $128–$1,495 $160
2024 $2,625 $498 $131–$1,540 $164
2025 $5,424 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $9,081 96 payments
  2. Boston Scientific Corporation $3,784 21 payments
  3. Saluda Medical Americas, Inc. $2,250 19 payments
  4. BIOTRONIK NRO, Inc. $1,367 19 payments
  5. SPR Therapeutics, Inc $490 9 payments
  6. Stryker Corporation $460 7 payments
  7. Nalu Medical, Inc. $374 4 payments
  8. Medtronic, Inc. $349 7 payments
  9. Relievant Medsystems, Inc. $319 5 payments
  10. MML US, Inc. $306 3 payments
  11. Other $604 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,493 163 payments
  2. Travel and Lodging $7,892 35 payments
Products named General payments · program years 2021–2025
  1. PROCLAIM Neuromodulation $2,952 21 payments
  2. PROCLAIM Neuromodulation $2,553 22 payments
  3. VERTIFLEX SUPERION $1,942 10 payments
  4. Evoke $1,354 8 payments
  5. Superion Indirect Decompression System $1,302 5 payments
  6. Prospera $1,157 16 payments
  7. PROCLAIM Structural Heart $996 10 payments
  8. ETERNA Structural Heart $977 11 payments
  9. ETERNA Neuromodulation $926 9 payments
  10. Evoke SCS $895 11 payments
  11. Other $5,287 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

610

Median for Anesthesiology: 322

Drug cost

$17,785

Median for Anesthesiology: $8,738

Branded share of claims

9.3%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 29 $6,047
Lidocaine Generic 13 $2,403
Pregabalin Generic 41 $2,176
Gabapentin Generic 82 $1,024
Celecoxib Generic 52 $892
Diclofenac Sodium Generic 29 $864
Buprenorphine Hcl Generic 14 $805
Morphine Sulfate Er Morphine Sulfate Brand 16 $544
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $527
Duloxetine Hcl Generic 57 $450

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 108 billing codes

Paid by Medicare

$98,442

Medicare's payments for the services billed

Medicare patients

475

Average age 75

Services billed

981

295 women, 180 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Diabetes 32%
Ischemic heart disease 29%
Osteoporosis 28%
Depression 27%
Chronic kidney disease 24%
Heart failure 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

198 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record